Provided by Tiger Trade Technology Pte. Ltd.

Tenaya Therapeutics Inc

0.6651
-0.0358-5.11%
Post-market: 0.66750.0024+0.36%19:49 EDT
Volume:2.29M
Turnover:1.56M
Market Cap:144.00M
PE:-1.12
High:0.7000
Open:0.6920
Low:0.6620
Close:0.7009
52wk High:2.35
52wk Low:0.3600
Shares:216.51M
Float Shares:205.84M
Volume Ratio:0.70
T/O Rate:1.11%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5922
EPS(LYR):-0.5922
ROE:-83.84%
ROA:-43.72%
PB:1.17
PE(LYR):-1.12

Loading ...

Tenaya Therapeutics (TNYA) Gets a Buy from Piper Sandler

TIPRANKS
·
Nov 10, 2025

Tenaya Therapeutics Q3 EPS $(0.12) Beats $(0.15) Estimate

Benzinga
·
Nov 10, 2025

Tenaya Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Reuters
·
Nov 10, 2025

Tenaya Therapeutics posts Q3 net loss of $20.3 million

Reuters
·
Nov 10, 2025

Tenaya Therapeutics Inc - Q3 Net Loss $20.3 Mln or $0.12 per Share

THOMSON REUTERS
·
Nov 10, 2025

Tenaya Therapeutics Shares Fall 3.9% Premarket After US FDA Places Clinical Hold on Co's Gene Therapy Trial for Rare Heart Disease

THOMSON REUTERS
·
Nov 10, 2025

Tenaya Therapeutics presents new interim safety, efficacy data on TN-201

TIPRANKS
·
Nov 10, 2025

Tenaya Therapeutics Presents Promising Interim Clinical Data From Mypeak™-1 Phase 1B/2a Clinical Trial of Tn-201 Gene Therapy for the Treatment of Mybpc3-Associated Hypertrophic Cardiomyopathy

THOMSON REUTERS
·
Nov 09, 2025

Tenaya Therapeutics Presents Promising Interim Clinical Data from MYPEAK™-1 Phase 1b/2a Clinical Trial of TN-201 Gene Therapy for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy

GlobeNewswire
·
Nov 09, 2025

BRIEF-Tenaya Therapeutics Inc - FDA Places Clinical Hold On Tenaya's Mypeak-1 Trial - SEC Filing

Reuters
·
Nov 08, 2025

Tenaya Therapeutics Inc - FDA Requests Protocol Amendment for Tenaya's Mypeak-1 Trial - SEC Filing

THOMSON REUTERS
·
Nov 08, 2025

Tenaya Therapeutics Inc - Expects No Impact on Tn-201 Timelines From Hold - SEC Filing

THOMSON REUTERS
·
Nov 08, 2025

FDA Places Clinical Hold on Tenaya Therapeutics' TN-201 Trial

Reuters
·
Nov 08, 2025

Tenaya Therapeutics Unveils Positive Interim Results for TN-201 Gene Therapy in Hypertrophic Cardiomyopathy Trial

Reuters
·
Nov 05, 2025

Tenaya Therapeutics Advances Genetic Therapy for Heart Disease: A Closer Look at the TN-201 Study

TIPRANKS
·
Oct 28, 2025

Tenaya Therapeutics’ ARVC Study: A Closer Look at AAV9 Antibody Prevalence

TIPRANKS
·
Oct 28, 2025

Tenaya Therapeutics Inc expected to post a loss of 15 cents a share - Earnings Preview

Reuters
·
Oct 25, 2025

Tenaya Therapeutics to Participate in HC Wainwright Genetic Medicines Virtual Conference

Reuters
·
Oct 10, 2025

Tenaya Therapeutics (TNYA): Evaluating Valuation Following CEO’s Spotlight at Cell & Gene Meeting on the Mesa

Simply Wall St.
·
Oct 10, 2025

Tenaya Therapeutics to Participate in Upcoming October Investor Conferences

GlobeNewswire
·
Oct 03, 2025